AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Akari Therapeutics Plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$9.89+1.71 (+20.90%)

Close on Oct 19, 2026

Market cap: $1.42T
P/E (TTM): –
Dividend yield: –

Akari Therapeutics Plc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Research & Development	2.82	6.98	5.45	9.56	9.13	8.82	8.74	12	23	17	5.80	1.62	1.28	1.48	0.84	0.25	–	–	–	–
Selling, General & Admin	9.28	9.66	11	14	8.08	9.16	8.22	12	12	9.94	5.50	0.30	2.33	2.18	1.41	0.55	–	–	–	–
Operating Expenses	17	22	17	23	17	18	17	21	38	27	31	1.92	–	–	–	–	–	–	–	–
Operating Income	-17	-22	-17	-23	-17	-18	-17	-21	-38	-27	-31	-1.92	-3.61	-3.67	-2.25	-0.79	–	–	–	–
Interest Expense	0.10	0.24	–	–	–	–	–	–	0	0	3.05	0.01	–	–	–	–	–	–	–	–
Interest & Investment Income	0.00	0.01	0.08	0.05	0.01	0.01	0.01	0.22	0.18	0.14	0.02	0.00	–	–	–	–	–	–	–	–
Other Non-Operating Income	-1.03	1.85	6.80	-0.14	-0.21	0.90	0.12	0.29	2.38	9.11	-15	-0.03	-0.01	-0.60	0.13	0.12	–	–	–	–
Merger & Restructuring Charges	-0.05	1.72	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	5.18	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	0	0	2.70	-2.70	0	0	–	–	–	–	–	–	–	–	–
Pretax Income	-18	-20	-10	-0.02	-17	-17	-17	-20	-35	-18	-45	-1.95	–	–	–	–	–	–	–	–
Income Tax Expense	-1.00	0	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–
Net Income	-17	-20	-10	-18	-17	-17	-17	-20	-35	-18	-45	-1.95	-3.62	-4.27	-2.12	-0.68	-1.01	-1.44	-3.13	-1.77
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	-9.65	-3.62	-4.30	-2.12	-0.68	–	–	–	–
EPS (Basic)(per share)	0.00	0.00	0.00	0.00	0.00	-0.01	-0.01	-0.01	-0.03	-0.02	-0.05	-0.02	-0.01	-0.03	-0.01	-0.0046	–	–	–	–
EPS (Diluted)(per share)	0.00	0.00	0.00	0.00	0.00	-0.01	-0.01	-0.01	-0.03	-0.02	-0.05	-0.02	-0.01	-0.03	-0.01	-0.0046	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	67,328	23,888	9,789	6,243	4,292	3,159	1,831	1,540	1,247	1,178	852	86	274	162	155	148	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	67,328	23,888	9,789	6,243	4,292	3,159	1,831	1,540	1,247	1,178	852	86	274	162	155	148	–	–	–	–
EBITDA	–	-22	-17	-23	-17	-18	-17	-21	-38	-27	-31	-1.91	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -68.4%

Financial strength

Current ratio: 0.60
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 55.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 76225.32
Dividend yield: –